Argonaute RNA specialises in simultaneous silencing of any two target genes with a single therapeutic. Primary focus is cardiometabolic. Most therapies either reduce steatosis or dyslipidaemia, often one at the expense of the other. Argonaute RNA demonstrates above 90% mRNA knockdown of both targets and synergistic reduction in disease risk factors. Unique linker technology differentiates from other bispecific approaches.

Data demonstrates remarkable tolerability in vivo and in vitro. No rise in transaminases or inflammatory markers/cytokines in vivo. No inflammatory signal in human PBMCs in vitro. Dramatic LDL-C reduction predicts >50% reduction in major adverse cardiovascular events in man. Compelling case to take this drug into clinical development for ASCVD and MASH/MASLD to ensure rapid deployment to patients in need.